Equities analysts forecast that Baxter International Inc (NYSE:BAX) will announce earnings per share of $0.68 for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Baxter International’s earnings. The highest EPS estimate is $0.68 and the lowest is $0.67. Baxter International posted earnings of $0.70 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 2.9%. The business is expected to announce its next quarterly earnings report before the market opens on Thursday, April 25th.
On average, analysts expect that Baxter International will report full year earnings of $3.27 per share for the current fiscal year, with EPS estimates ranging from $3.25 to $3.29. For the next fiscal year, analysts forecast that the firm will post earnings of $3.70 per share, with EPS estimates ranging from $3.65 to $3.75. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Baxter International.
Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, January 31st. The medical instruments supplier reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The business had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.80 billion.
Baxter International stock traded down $0.06 during trading on Friday, hitting $74.33. 4,054,375 shares of the company were exchanged, compared to its average volume of 3,100,136. Baxter International has a 52 week low of $61.05 and a 52 week high of $82.25. The company has a market capitalization of $37.99 billion, a P/E ratio of 24.37, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02. The company has a current ratio of 2.09, a quick ratio of 1.50 and a debt-to-equity ratio of 0.44.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 1st. Shareholders of record on Friday, March 1st were paid a $0.19 dividend. The ex-dividend date was Thursday, February 28th. This represents a $0.76 dividend on an annualized basis and a yield of 1.02%. Baxter International’s dividend payout ratio (DPR) is presently 24.92%.
In other Baxter International news, Director Thomas T. Stallkamp sold 1,638 shares of the company’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $73.75, for a total value of $120,802.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter S. Hellman sold 5,680 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $81.89, for a total value of $465,135.20. Following the completion of the transaction, the director now owns 28,774 shares of the company’s stock, valued at approximately $2,356,302.86. The disclosure for this sale can be found here. Insiders sold a total of 95,099 shares of company stock valued at $7,175,949 in the last 90 days. Corporate insiders own 0.70% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Gantzert Investment Co. LLC ADV purchased a new position in shares of Baxter International during the 4th quarter valued at $25,000. Parisi Gray Wealth Management purchased a new position in shares of Baxter International during the 4th quarter valued at $26,000. Sontag Advisory LLC purchased a new position in shares of Baxter International during the 4th quarter valued at $30,000. Baldwin Brothers Inc. MA lifted its position in shares of Baxter International by 904.0% during the 4th quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 452 shares during the last quarter. Finally, We Are One Seven LLC purchased a new stake in Baxter International during the 4th quarter worth about $34,000. Hedge funds and other institutional investors own 86.45% of the company’s stock.
About Baxter International
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Read More: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.